Fifty-six effective active ingredients of CFDT were obtained, 3,878 genes related to obese PCOS were obtained, and 309 potential drug targets were obtained, of which TP53, AKT1, STAT3, JUN, and SRC were the top five targets. This evidence concerns the gene TP53 and polycystic ovary syndrome.